Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;14(4):2188-2191.
doi: 10.21037/tcr-2024-2207. Epub 2025 Apr 24.

Osimertinib-chemotherapy synergy in EGFR-mutant NSCLC: advancing central nervous system control amidst toxicity considerations

Rahul Kumar #  1 , Emily Miao #  1   2 , Luke Roy George Pike  1
Affiliations
Editorial

Osimertinib-chemotherapy synergy in EGFR-mutant NSCLC: advancing central nervous system control amidst toxicity considerations

Rahul Kumar et al. Transl Cancer Res. .
No abstract available

Keywords: Epidermal growth factor receptor-mutated non-small cell lung cancer (EGFR-mutated NSCLC); brain metastases (BMs); central nervous system efficacy (CNS efficacy); combination therapy; osimertinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2024-2207/coif). L.R.G.P. has received grants or contracts from the Department of Defense for the Lung Idea Award for Brain Mets Research, Caris Life Sciences for IIT Genomic Sequencing, and Harbinger Health, Genece Health, and Delfi Diagnostics for early detection trials. No royalties or licenses were disclosed. He also received consulting fees from Dxcover Limited, Genece Health, Inc., and Monograph Capital Advisors, L.P. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2023;389:1935-48. 10.1056/NEJMoa2306434 - DOI - PubMed
    1. Jänne PA, Planchard D, Kobayashi K, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2024;42:808-20. 10.1200/JCO.23.02219 - DOI - PMC - PubMed
    1. Malhotra J, Mambetsariev I, Gilmore G, et al. Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review. JAMA Oncol 2025;11:60-9. 10.1001/jamaoncol.2024.5218 - DOI - PubMed
    1. Singh K, Saxena S, Khosla AA, et al. Update on the Management of Brain Metastasis. Neurotherapeutics 2022;19:1772-81. 10.1007/s13311-022-01312-w - DOI - PMC - PubMed
    1. Upadhyay R, Palmer JD, Klamer BG, et al. Safety and Feasibility of Stereotactic Radiosurgery for Patients with 15 or more Brain Metastases. Adv Radiat Oncol 2024;9:101509. 10.1016/j.adro.2024.101509 - DOI - PMC - PubMed

LinkOut - more resources